Successful treatment of a VIPoma by continuous subcutaneous infusion of somatostatin analogue (SMS 201-995).

Abstract

A case with WDHA syndrome due to VIPoma is reported. Injection of somatostatin analogue SMS 201-995 was followed by prompt suppression of vasoactive intestinal polypeptide levels (VIP), decreased stool volume, and restoration of the serum potassium concentration to normal. Long-term treatment with SMS 201-995 for up to 20 weeks produced excellent clinical control and a decrease in tumour size. No adverse effects were noted except for localized pain at the site of injection. This was overcome by using a continuous subcutaneous infusion pump which also enabled the effective daily dosage to be reduced and thereby adverse reactions to be avoided.

• Authors: Y Niitsu, Y Goto, M Maeda, N Tsushima, N Watanabe, Y Kohgo, I Urushizaki
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 2 Issue 3 Pg. 269-79 (Jun 1988) ISSN: 0269-2813 [Print] England
• PMID: 2856504 (Publication Type: Case Reports, Journal Article)

Chemical References

• Octreotide

Topics

• Female
• Humans
• Infusions, Intravenous
• Middle Aged
• Octreotide (administration & dosage, therapeutic use)
• Pancreatic Neoplasms (drug therapy)
• Vipoma (drug therapy)